Ignyta Buys Personalized Medicine Firm Actagene | GenomeWeb

NEW YORK (GenomeWeb News) – Ignyta said on Monday it has acquired biotech firm Actagene for an undisclosed amount.

The deal, according to Ignyta, will transition it from a company focused solely on molecular diagnostics for autoimmune diseases to "an integrated Rx/Dx focus on drug and biomarker discovery and development for cancer and immunology."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.